Imiquimod
- Generic Name
- Imiquimod
- Brand Names
- Aldara, Vyloma, Zyclara
- Drug Type
- Small Molecule
- Chemical Formula
- C14H16N4
- CAS Number
- 99011-02-6
- Unique Ingredient Identifier
- P1QW714R7M
- Background
Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and cont...
- Indication
For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
- Associated Conditions
- Actinic Keratoses of the face, Actinic Keratoses of the scalp, Condylomata Acuminata, Herpes Simplex Infections, Molluscum Contagiosum, Superficial Basal Cell Carcinoma
- Associated Therapies
- -
Radiotherapy or Imiquimod in Complex Lentigo Maligna
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 126
- Registration Number
- NCT02394132
- Locations
- 🇳🇿
North Shore Hospital, Takapuna, Auckland, New Zealand
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Skin and Cancer Foundation, Sydney, New South Wales, Australia
Topical 5% Imiquimod Cream for Vulvar Paget's Disease
- Conditions
- Interventions
- First Posted Date
- 2015-03-11
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- University Medical Center Nijmegen
- Target Recruit Count
- 25
- Registration Number
- NCT02385188
- Locations
- 🇳🇱
Radboudumc, Nijmegen, Netherlands
🇳🇱University Medical Centre Utrecht, Utrecht, Netherlands
🇳🇱Netherlands Cancer Institute, Amsterdam, Netherlands
The Real Life Topical Field Treatment of Actinic Keratosis Study
- Conditions
- Interventions
- First Posted Date
- 2015-02-12
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 1168
- Registration Number
- NCT02362152
- Locations
- 🇳🇱
Lievensberg Ziekenhuis, Bergen op Zoom, Netherlands
Imiquimod Treatment of CIN Lesions
- Conditions
- Interventions
- First Posted Date
- 2014-12-31
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Maastricht University Medical Center
- Target Recruit Count
- 9
- Registration Number
- NCT02329171
- Locations
- 🇳🇱
Maastricht University Medical Centre, Maastricht, Netherlands
IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis
- First Posted Date
- 2014-11-02
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- Maastricht University Medical Center
- Target Recruit Count
- 624
- Registration Number
- NCT02281682
- Locations
- 🇳🇱
Maastricht UMC, Maastricht, Limburg, Netherlands
HER2-Peptide Vaccination of Patients With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Technical University of Munich
- Target Recruit Count
- 2
- Registration Number
- NCT02276300
- Locations
- 🇩🇪
III.Medizinische Klinik und Poliklinik, Klinikum rechts der Isar der TUM, Munic, Bavaria, Germany
Pilot Study of DRibble Vaccine for Prostate Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- UbiVac
- Target Recruit Count
- 3
- Registration Number
- NCT02234921
- Locations
- 🇺🇸
Providence Health & Services, Portland, Oregon, United States
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
- Conditions
- Interventions
- First Posted Date
- 2014-05-12
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- AIDS Malignancy Consortium
- Target Recruit Count
- 4446
- Registration Number
- NCT02135419
- Locations
- 🇺🇸
Anal Dysplasia Clinic MidWest, Chicago, Illinois, United States
🇺🇸The Polyclinic, Seattle, Washington, United States
🇺🇸Virginia Mason Medical Center, Seattle, Washington, United States
Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix
- Conditions
- Interventions
- First Posted Date
- 2014-05-05
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- United States Naval Medical Center, San Diego
- Target Recruit Count
- 22
- Registration Number
- NCT02130323
- Locations
- 🇺🇸
Naval Medical Center San Diego, San Diego, California, United States
A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses
- Conditions
- Interventions
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 467
- Registration Number
- NCT02120898
- Locations
- 🇺🇸
Site 13, Fridley, Minnesota, United States
🇺🇸Site 11, Wilmington, North Carolina, United States
🇺🇸Site 6, Knoxville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.